Cargando…
Who should receive oral antiviral therapy for severe acute respiratory syndrome coronavirus 2 infection in the omicron era? Choose wisely
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9728013/ https://www.ncbi.nlm.nih.gov/pubmed/36496153 http://dx.doi.org/10.1016/j.cmi.2022.11.028 |
| _version_ | 1784845154936422400 |
|---|---|
| author | Weiss, Guenter |
| author_facet | Weiss, Guenter |
| author_sort | Weiss, Guenter |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9728013 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-97280132022-12-07 Who should receive oral antiviral therapy for severe acute respiratory syndrome coronavirus 2 infection in the omicron era? Choose wisely Weiss, Guenter Clin Microbiol Infect Commentary European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. 2023-03 2022-12-07 /pmc/articles/PMC9728013/ /pubmed/36496153 http://dx.doi.org/10.1016/j.cmi.2022.11.028 Text en © 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Commentary Weiss, Guenter Who should receive oral antiviral therapy for severe acute respiratory syndrome coronavirus 2 infection in the omicron era? Choose wisely |
| title | Who should receive oral antiviral therapy for severe acute respiratory syndrome coronavirus 2 infection in the omicron era? Choose wisely |
| title_full | Who should receive oral antiviral therapy for severe acute respiratory syndrome coronavirus 2 infection in the omicron era? Choose wisely |
| title_fullStr | Who should receive oral antiviral therapy for severe acute respiratory syndrome coronavirus 2 infection in the omicron era? Choose wisely |
| title_full_unstemmed | Who should receive oral antiviral therapy for severe acute respiratory syndrome coronavirus 2 infection in the omicron era? Choose wisely |
| title_short | Who should receive oral antiviral therapy for severe acute respiratory syndrome coronavirus 2 infection in the omicron era? Choose wisely |
| title_sort | who should receive oral antiviral therapy for severe acute respiratory syndrome coronavirus 2 infection in the omicron era? choose wisely |
| topic | Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9728013/ https://www.ncbi.nlm.nih.gov/pubmed/36496153 http://dx.doi.org/10.1016/j.cmi.2022.11.028 |
| work_keys_str_mv | AT weissguenter whoshouldreceiveoralantiviraltherapyforsevereacuterespiratorysyndromecoronavirus2infectionintheomicronerachoosewisely |